<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000662028">
  <TermName>veltuzumab</TermName>
  <TermPronunciation>(vel-TOO-zoo-mab)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance being studied in the treatment of several types of lymphoma. It binds to the protein CD20, which is found on B cells (a type of immune system cell) and some types of lymphoma cells. This causes the immune system to kill the cancer cells. Veltuzumab is a type of monoclonal antibody. Also called hA20, HCD20, and IMMU-106.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000726029" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;veltuzumab&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000726028" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;veltuzumab&quot;" language="es" id="_4"/>
  <SpanishTermName>veltuzumab</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento de varios tipos de linfoma. Se une a la proteína CD20, que se encuentra en las células B (tipo de célula del sistema inmunitario) y a algunos tipos de células de linfomas. Hace que el sistema inmunitario destruya las células cancerosas. El veltuzumab es un tipo de anticuerpo monoclonal. También se llama hA20, HCD20 e IMMU-106.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2010-04-07</DateFirstPublished>
  <DateLastModified>2010-04-07</DateLastModified>
</GlossaryTerm>
